|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||39.52 - 40.83|
|52 Week Range||32.53 - 59.59|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.17|
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Acceleron Pharma Inc...
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Directors and will continue to serve the organization in an advisory capacity as Director Emeritus. “Tom co-founded Acceleron in 2003 and has been on the Board from day one,” said Francois Nader, MD, Chairman of Acceleron Pharma. “During this period, Tom’s unparalleled scientific instincts and acumen were instrumental in turning a belief in the promise of a fundamental biological pathway into a company on the verge of delivering its first product to patients.
Shares of biotech company Celgene rose Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY. A live audio webcast will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.
Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 74 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
– Luspatercept Biologics License Application and Marketing Authorization Application submitted in April 2019 –
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
For the fiscal third quarter, Telenav (TNAV) expects total revenues between $49 million and $53 million, while net loss is anticipated to be $7 million-$9 million.
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.
Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation.
Investors can buy low cost index fund if they want to receive the average market return. But if you invest in individual stocks, some are likely to underperform. Unfortunately for shareholders, while the Acceleron Pharma...